Gunderson Dettmer represented client Evident Vascular, a medical technology startup, in its $35 million Series A financing led by Vensana Capital. Evident Vascular is leveraging AI to develop an advanced intravascular ultrasound (IVUS) platform technology designed initially for peripheral vascular interventions, with future capability for coronary procedures.

In the announcement of the transaction, Evident Vascular CEO and co-founder Howard Rosen said, “Legacy IVUS platforms were originally designed primarily for coronary procedures and secondarily for peripheral vascular applications. Shortcomings in image quality, interpretation, and workflow have limited the widespread adoption of IVUS despite its clinical benefit, and there has been minimal innovation to address these limitations. Along with my co-founders, Chief Technology Officer Patrick Phillips, Ph.D., and Chief Product Officer Danielo Piazza, our team is pioneering the future of intravascular imaging with a platform optimized for peripheral vascular procedures that will enable improved image interpretation guidance, and ease of use enhancements throughout the clinical workflow.”

The Gunderson Dettmer deal team was led by Rich Hesp and included Laura Stoffel, Morgan Clarke and Marna Pattaropong. 

Companies
Evident Vascular
Vensana Capital